• Impact Therapeutics nominated IMP2794 as a preclinical candidate, its first from a proprietary targeted protein degradation platform.
• Program targets KAT6A with a PROTAC degrader, showing more than 1,000-fold selectivity over KAT6B.
• Preclinical data showed in vitro tumor-cell cytotoxicity with minimal hematopoietic toxicity.
• In vivo studies showed antitumor activity in breast cancer CDX models, including both sensitive and insensitive settings.
• High oral bioavailability across multiple rodent and non-rodent species supported potential for strong human systemic exposure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260812-12281384), on August 12, 2026, and is solely responsible for the information contained therein.